09:35 AM EST - Revive Therapeutics Ltd. : Provided an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial ( NCT04504734 ) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. In collaboration with Delta Health, the Study is targeting clinicals sites operated by MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 clinical research sites and over 6000 in-patient hospital beds. As previously mentioned, the Company has selected 13 clinical research sites to complete enrollment of the Study. Revive Therapeutics Ltd.
shares C.RVV are trading off 1 cent at $0.22.
